Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Evaluating a new drug is difficult for the pharmaceutical community

Hans Duvefelt, MD
Meds
December 9, 2010
Share
Tweet
Share

New medicines are like new fashions in clothing. They are introduced with great fanfare. Most turn out to seem fairly ordinary after a few years. Some are quickly forgotten or discarded and make us say: “What was I thinking?”

Evaluating a new drug is difficult, for the pharmaceutical and scientific communities as well as for us clinicians. It often takes years of general use before a drug can really prove its safety or usefulness.

As physicians with responsibility for our patients’ lives and well-being, we need to balance our desire to provide the best treatment with our obligation to avoid unnecessary risk. Unfortunately, many new drugs turn out to be less safe than we are told when they are first introduced. The increasingly common sources of drug information, advertisements and pharmaceutical representatives, also don’t tell you what the serious journals say about new medications. It is our duty as practicing physicians to keep up with the leading medical journals.

I may sound old-fashioned at times when I question new treatments or hold off on using them for a while, but I have seen enough new drugs hit the market and soon be withdrawn because of safety issues that were not known or understood when the medicines were first approved.

Most people still remember Vioxx, the arthritis medication that wouldn’t cause ulcers. Early on we heard about high blood pressures and fluid retention. The heart attack risk was apparently kept secret for a while before the drug was withdrawn.

I prescribed a fair amount of Vioxx, because all the other arthritis medications could also cause fluid retention and Vioxx seemed to work quite well. I had also almost lost a patient to a sudden intestinal hemorrhage from indomethacin once, so the stomach safety seemed like a valid selling point.

Before Vioxx, there was Duract, an anti-inflammatory pain medication for short-term use. It was eliminated through the liver instead of through the kidneys, like other anti-inflammatory medications. I never had time to prescribe it. I held off, because it was a new type of drug, and it was soon withdrawn amid reports of liver failure.

Some medications for Type 2 Diabetes bother me. Rezulin was the first drug in a new class, which makes the body more sensitive to its own insulin. Before I had warmed up to prescribing it, the drug was withdrawn. It was linked to liver toxicity. The two newer drugs in the same class, Avandia and Actos, seem safer on the liver, but from early on, there were concerns over fluid retention and heart failure risk. In 2007 Avandia was shown to increase heart attack risk by over 40%. Actos has so far looked safer, but I am still very nervous about it.

When the Scandinavian Simvastatin Survival Study (4-S) showed that deaths from heart attacks could be reduced by 30% with Zocor, I felt fairly comfortable prescribing it for patients with high cholesterol.  I had not really used the statin drugs that came before it, because there was no proof they reduced heart disease risk. I was still cautious with Zocor, because the cholesterol-lowering drug that came before the statins, Atromid-S, was associated with a surprising and unexplained increase in death rates by over 40%.

With every statin drug that came after Zocor, I stubbornly waited for “outcomes data” of some sort. One by one, the newer drugs proved themselves to fight atherosclerosis and heart disease, and I have ended up using all of them.

Baycol came along and made claims of having less risk for muscle damage, rhabdomyolysis, than the other members of the class. I tried it, but as it didn’t have outcomes data yet, I reserved my use of it to patients who couldn’t tolerate the other statins. Ironically, Baycol was taken off the market because it had a much higher risk of rhabdomyolysis than the other statin drugs.

I have seen many new drugs come and go, from diet pills like Redux to antibiotics like Omniflox, Tequin and Ketek during my thirty years in medicine. I also vividly remember the Thalidomide-induced limb deformities of my classmate in Junior High School in Sweden. Thalidomide was marketed there as a safe drug for morning sickness.

One of my professors in medical school said about medications for high blood pressure that they needed to have no serious or annoying side effects and be less dangerous than the condition for which they are intended. I have held on to his wisdom all these years.

ADVERTISEMENT

A patient with an acute, life-threatening condition may be very willing to accept a certain risk if the treatment is effective. Even an unproven treatment may be the best option when older treatments are known to be risky or not very effective.

I question the value of being an early adopter of new drugs under normal circumstances, when slightly older drugs are still useful. Why use our patients for guinea pigs?

A Country Doctor is a family physician who blogs at A Country Doctor Writes:.

Submit a guest post and be heard.

Prev

Stercoral perforation as a deadly cause of colon rupture

December 9, 2010 Kevin 6
…
Next

Health IT and doctors need to bridge the cultural gap

December 9, 2010 Kevin 14
…

Tagged as: Medications

Post navigation

< Previous Post
Stercoral perforation as a deadly cause of colon rupture
Next Post >
Health IT and doctors need to bridge the cultural gap

ADVERTISEMENT

More by Hans Duvefelt, MD

  • The art of asking where it hurts

    Hans Duvefelt, MD
  • Thinking like a plumber when adjusting medications

    Hans Duvefelt, MD
  • The American food conspiracy

    Hans Duvefelt, MD

More in Meds

  • How drugmakers manipulate your health from diagnosis to prescription

    Martha Rosenberg
  • The food-drug interaction risks your doctor may be missing

    Frank Jumbe
  • Why retail pharmacies are the future of diverse clinical trials

    Shelli Pavone
  • Why does rifaximin cost 95 percent more in the U.S. than in Asia?

    Jai Kumar, MD, Brian Nohomovich, DO, PhD and Leonid Shamban, DO
  • A world without antidepressants: What could possibly go wrong?

    Tomi Mitchell, MD
  • The truth about GLP-1 medications for weight loss: What every patient should know

    Nisha Kuruvadi, DO
  • Most Popular

  • Past Week

    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • How community paramedicine impacts Indigenous elders

      Noah Weinberg | Conditions
    • Why Canada is losing its skilled immigrant doctors

      Olumuyiwa Bamgbade, MD | Physician
    • How to speak the language of leadership to improve doctor wellness [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Why tracking cognitive load could save doctors and patients

      Hiba Fatima Hamid | Education
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • How medical culture hides burnout in plain sight

      Marco Benítez | Conditions
  • Recent Posts

    • Why Canada is losing its skilled immigrant doctors

      Olumuyiwa Bamgbade, MD | Physician
    • Why doctors are reclaiming control from burnout culture

      Maureen Gibbons, MD | Physician
    • Would The Pitts’ Dr. Robby Robinavitch welcome a new colleague? Yes. Especially if their initials were AI.

      Gabe Jones, MBA | Tech
    • Why medicine must stop worshipping burnout and start valuing humanity

      Sarah White, APRN | Conditions
    • Why screening for diseases you might have can backfire

      Andy Lazris, MD and Alan Roth, DO | Physician
    • How organizational culture drives top talent away [PODCAST]

      The Podcast by KevinMD | Podcast

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 1 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • How community paramedicine impacts Indigenous elders

      Noah Weinberg | Conditions
    • Why Canada is losing its skilled immigrant doctors

      Olumuyiwa Bamgbade, MD | Physician
    • How to speak the language of leadership to improve doctor wellness [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Why tracking cognitive load could save doctors and patients

      Hiba Fatima Hamid | Education
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • How medical culture hides burnout in plain sight

      Marco Benítez | Conditions
  • Recent Posts

    • Why Canada is losing its skilled immigrant doctors

      Olumuyiwa Bamgbade, MD | Physician
    • Why doctors are reclaiming control from burnout culture

      Maureen Gibbons, MD | Physician
    • Would The Pitts’ Dr. Robby Robinavitch welcome a new colleague? Yes. Especially if their initials were AI.

      Gabe Jones, MBA | Tech
    • Why medicine must stop worshipping burnout and start valuing humanity

      Sarah White, APRN | Conditions
    • Why screening for diseases you might have can backfire

      Andy Lazris, MD and Alan Roth, DO | Physician
    • How organizational culture drives top talent away [PODCAST]

      The Podcast by KevinMD | Podcast

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Evaluating a new drug is difficult for the pharmaceutical community
1 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...